fumarylacetoacetate and Tyrosinemias

fumarylacetoacetate has been researched along with Tyrosinemias* in 6 studies

Reviews

2 review(s) available for fumarylacetoacetate and Tyrosinemias

ArticleYear
[Hereditary tyrosinemia: an endoplasmic reticulum stress disorder?].
    Medecine sciences : M/S, 2003, Volume: 19, Issue:10

    Hereditary tyrosinemia type 1 (HT1) is the most severe metabolic disease associated with tyrosine catabolism. An accumulation of toxic metabolites seems responsible for the pathology of HT1. The metabolite fumarylacetoacetate, accumulating due to a deficiency in fumarylacetoacetate hydrolase, displays apoptogenic, mutagenic, aneugenic and mitogenic activities. These effects may underlie the tumorigenic phenomenon observed in HT1. Fumarylacetoacetate in addition to causing disturbances in Ca2+ homeostasis, may induce endoplasmic reticulum stress.

    Topics: Acetoacetates; Calcium; Endoplasmic Reticulum; Homeostasis; Humans; Hydrolases; Tyrosinemias

2003
[Inborn errors of tyrosine metabolism: abnormalities in catabolic pathway of phenylalanine and tyrosine].
    Seikagaku. The Journal of Japanese Biochemical Society, 1999, Volume: 71, Issue:11

    Topics: 4-Hydroxyphenylpyruvate Dioxygenase; Acetoacetates; Amino Acid Metabolism, Inborn Errors; Animals; Humans; Mice; Mutation; Phenylalanine; Tyrosine; Tyrosinemias

1999

Other Studies

4 other study(ies) available for fumarylacetoacetate and Tyrosinemias

ArticleYear
Fumarylacetoacetate inhibits the initial step of the base excision repair pathway: implication for the pathogenesis of tyrosinemia type I.
    Journal of inherited metabolic disease, 2013, Volume: 36, Issue:5

    Hereditary tyrosinemia type I (HT1) is an autosomal recessive disease caused by a deficiency in human fumarylacetoacetate (FAA) hydrolase (FAH), which is the last enzyme in the catabolic pathway of tyrosine. Several reports suggest that intracellular accumulation of intermediates of tyrosine catabolism, such as FAA and succinylacetone (SA) is important for the pathogenesis in liver and kidney of HT1 patients. In this work, we examined the effect of FAA and SA on DNA glycosylases initiating base excision repair (BER), which is the most important pathway for removing mutagenic DNA base lesions. In vitro assays monitoring DNA glycosylase activities demonstrated that FAA but not SA inhibited base removal. In particular, the Neil1 and Neil2 DNA glycosylases were strongly inhibited, whereas inhibition of Nth1 and Ogg1 were less efficient. These DNA glycosylases initiate excision of a broad range of mutagenic oxidative base lesions. Further, FAA showed a modest inhibitory effect on the activity of the alkylbase DNA glycosylase Aag and no significant inhibition of the uracil DNA glycosylase Ung2. These data indicate that FAA inhibition of DNA glycosylases removing oxidative base lesions in HT1 patients may increase mutagenesis, suggesting an important mechanism for development of hepatocarcinoma and somatic mosaicism.

    Topics: Acetoacetates; Deoxyribonuclease (Pyrimidine Dimer); DNA; DNA Glycosylases; DNA Repair; DNA-(Apurinic or Apyrimidinic Site) Lyase; Heptanoates; Humans; Mutagenesis; Tyrosinemias

2013
Involvement of endoplasmic reticulum stress in hereditary tyrosinemia type I.
    The Journal of biological chemistry, 2006, Mar-03, Volume: 281, Issue:9

    Hereditary tyrosinemia type I (HTI) is the most severe disease of the tyrosine degradation pathway. HTI is caused by a deficiency of fumarylacetoacetate hydrolase (FAH), the enzyme responsible for the hydrolysis of fumarylacetoacetate (FAA). As a result, there is an accumulation of metabolites such as maleylacetoacetate, succinylacetone, and FAA. The latter was shown to display mutagenic, cytostatic, and apoptogenic activities and to cause chromosomal instability. Herein, we demonstrate that FAA also causes a cellular insult leading to the endoplasmic reticulum (ER) stress signaling. Treatment of V79 Chinese hamster lung cells with an apoptogenic dose of FAA (100 mum) causes an early induction of the ER resident chaperone GRP78/BiP and a simultaneous phosphorylation of the eIF2alpha. FAA treatment also causes a subsequent induction of the proapoptotic CHOP (CEBP homologous protein) transcription factor as well as a late activation of caspase-12. Data obtained from fah(-/-) mice taken off the therapeutic 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3 cyclohexanedione drug are similar. However, in this mouse model, there is also an increase in proteasome activity indicative of ER-associated degradation. This difference observed between the two models may be due to the fact that the murine model measures the effects of all metabolites accumulating in hereditary tyrosinemia type I as opposed to the cellular model that only measures the effects of exogenous FAA.

    Topics: Acetoacetates; Animals; Cell Line; Cricetinae; Cyclohexanones; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Enzyme Inhibitors; Eukaryotic Initiation Factor-2; Heat-Shock Proteins; Humans; Hydrolases; Liver; Lung; Mice; Mice, Knockout; Molecular Chaperones; Nitrobenzoates; Proteasome Endopeptidase Complex; Signal Transduction; Transcription, Genetic; Tyrosinemias

2006
Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability.
    Human molecular genetics, 2001, Aug-15, Volume: 10, Issue:17

    Patients suffering from the metabolic disease hereditary tyrosinemia type I (HT1), caused by fumarylacetoacetate hydrolase deficiency, have a high risk of developing liver cancer. We report that a sub-apoptogenic dose of fumarylacetoacetate (FAA), the mutagenic metabolite accumulating in HT1, induces spindle disturbances and segregational defects in both rodent and human cells. Mitotic abnormalities, such as distorted spindles, lagging chromosomes, anaphase/telophase chromatin bridges, aberrant karyokinesis/cytokinesis and multinucleation were observed. Some mitotic asters displayed a large pericentriolar material cloud and/or altered distribution of the spindle pole-associated protein NuMA. FAA-treated cells developed micronuclei which were predominantly CREST-positive, suggesting chromosomal instability. The Golgi complex was rapidly disrupted by FAA, without evident microtubules/tubulin alterations, and a sustained activation of the extracellular signal-regulated protein kinase (ERK) was also observed. Primary skin fibroblasts derived from HT1 patients, not exogenously treated with FAA, showed similar mitotic-derived alterations and ERK activation. Biochemical data suggest that FAA causes ERK activation through a thiol-regulated and tyrosine kinase-dependent, but growth factor receptor- and protein kinase C-independent pathway. Pre-treatment with the MEK inhibitor PD98059 and the Ras farnesylation inhibitor B581 decreased the formation of CREST-positive micronuclei by approximately 75%, confirming the partial contribution of the Ras/ERK effector pathway to the induction of chromosomal instability by FAA. Replenishment of intracellular glutathione (GSH) with GSH monoethylester abolished ERK activation and reduced the chromosomal instability induced by FAA by 80%. Together these results confirm and extend the previously reported genetic instability occurring in cells from HT1 patients and allow us to speculate that this tumorigenic-related phenomenon may rely on the biochemical/cellular effects of FAA as a thiol-reacting and organelle/mitotic spindle-disturbing agent.

    Topics: Acetoacetates; Animals; Cell Line; Chromosome Aberrations; Cricetinae; Fluorescent Antibody Technique; G2 Phase; Glutathione; Golgi Apparatus; HeLa Cells; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Mitosis; Phosphorylation; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Spindle Apparatus; Tyrosine; Tyrosinemias

2001
In vivo suppressor mutations correct a murine model of hereditary tyrosinemia type I.
    Proceedings of the National Academy of Sciences of the United States of America, 1999, Oct-12, Volume: 96, Issue:21

    Hereditary tyrosinemia type I and alkaptonuria are disorders of tyrosine catabolism caused by deficiency of fumarylacetoacetate hydrolase (FAH) and homogentisic acid dioxygenase (HGD), respectively. Tyrosinemia is a severe childhood disease that affects the liver and kidneys, but alkaptonuria is a more benign adult disorder in comparison. Because HGD is upstream of FAH in the tyrosine pathway, mice doubly mutant in both enzymes were found to be protected from the liver and renal damage of tyrosinemia as hypothesized. Mice mutant at the tyrosinemic locus but heterozygous for alkaptonuria spontaneously developed clonal nodules of functionally normal hepatocytes that were able to rescue the livers of some mice with this genotype. This phenotypic rescue was a result of an inactivating mutation of the wild-type homogentisic acid dioxygenase gene, thus presenting an example of an in vivo suppressor mutation in a mammalian model.

    Topics: Acetoacetates; Alanine Transaminase; Animals; Cloning, Molecular; Crosses, Genetic; Disease Models, Animal; Ethylnitrosourea; Gene Conversion; Gene Deletion; Genotype; Heterozygote; Liver; Loss of Heterozygosity; Mice; Mice, Knockout; Models, Genetic; Mutagenesis; Precancerous Conditions; Reverse Transcriptase Polymerase Chain Reaction; Suppression, Genetic; Tyrosine; Tyrosinemias

1999